Group 1 - The core viewpoint of the news is that Maide Medical's stock has seen a significant decline, with a closing price of 15.46 yuan, up 3.76%, and a market-to-book ratio of 3.27, marking a new low in 240 days, with a total market value of 2.57 billion yuan [1] - As of March 31, 2025, the number of shareholders in Maide Medical has increased to 3,997, up by 163, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Group 2 - The latest financial results for the first quarter of 2025 show that Maide Medical achieved operating revenue of 40.18 million yuan, a year-on-year decrease of 45.87%, and a net profit loss of approximately 10.80 million yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company has received recognition for its innovation and intellectual property, being awarded the status of a national intellectual property advantage enterprise and a provincial intellectual property demonstration enterprise in 2022 [1] - In comparison to industry averages, Maide Medical's price-to-earnings (PE) ratio (TTM) is -62.23, and its market-to-book ratio is 3.27, indicating a significant deviation from the industry average PE ratio of 60.89 and market-to-book ratio of 4.16 [2]

Group 1 - The core viewpoint of the news is that Maide Medical has successfully launched China's first integrated tungsten-free, glue-free, and silicone oil-free pre-filled syringe in collaboration with Nanjing Batefly, marking a significant step for domestic high-end medical consumables to enter the international market [1] - Maide Medical has developed an automated production line for Batefly, incorporating advanced technologies such as X-ray intelligent detection and micro-level collaborative control, achieving millisecond detection speed and zero glue residue risk, thus overcoming long-standing technological monopolies by foreign companies [1] - Batefly's core product, the silicone oil-free COC pre-filled syringe, has successfully passed the FDA Drug Master File (DMF) registration, indicating its readiness for international markets [1] Group 2 - Maide Medical aims to deepen strategic cooperation with industry leaders like Nanjing Batefly, leveraging its expertise in intelligent equipment to build a new ecosystem for intelligent manufacturing of medical consumables [2] - The medical device industry in China is entering a phase of high-quality development, driven by factors such as an aging population and increasing healthcare expenditures, with projections indicating that the market size may exceed 1.8 trillion yuan by 2030, with a compound annual growth rate of 7.53% from 2025 to 2030 [2] - Continuous policy support, expanding market demand, and steady improvements in production automation are creating a synergistic effect that drives the development of the intelligent medical consumables equipment industry [2] Group 3 - After over 20 years of development, Maide Medical has become a national high-tech enterprise in the medical device industry, focusing on innovation and increasing R&D investment, with R&D expenses reaching 40.41 million yuan in 2024, a year-on-year increase of 21.81% [3] - The company submitted 146 patent applications in 2024, including 21 invention patents, and received 78 new patent authorizations, with a total of 416 authorized patents by the end of 2024 [3] - In the first quarter of 2025, R&D investment was 9.156 million yuan, accounting for 22.79% of revenue, reflecting a year-on-year increase of 9.48 percentage points [3] Group 4 - Maide Medical's products have received multiple national and provincial recognitions, including being listed as key products at various levels, showcasing its commitment to quality and innovation [4] - The company is actively exploring new growth areas, including high-value medical consumables and clinical testing, while integrating advanced intelligent control systems to provide customized digital workshop solutions [4] - Maide Medical is pushing the industry towards intelligent and flexible production models, enhancing its competitive edge in the market [4]

Company Overview - Maide Medical's stock closed at 14.61 yuan, up 1.67%, with a latest price-to-book ratio of 3.09, marking a new low in 231 days, and a total market capitalization of 2.428 billion yuan [1] - As of the first quarter of 2025, five institutions held shares in Maide Medical, including three funds, one other entity, and one social security fund, with a total holding of 15.2835 million shares valued at 179 million yuan [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Performance Metrics - For the first quarter of 2025, Maide Medical reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87%, and a net profit of -10,797,370.24 yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company's price-to-earnings ratio (TTM) is -58.81, and the static PE is -121.54, with a market capitalization of 2.428 billion yuan [2] - The industry average PE (TTM) is 60.04, and the industry median is 49.67, indicating that Maide Medical's valuation metrics are significantly lower than the industry averages [2]

Core Viewpoint - MaiDe Medical's stock closed at 14.03 yuan, up 3.47%, with a latest price-to-book ratio of 2.97, marking a new low in 156 days, and a total market capitalization of 2.332 billion yuan [1] Group 1: Company Overview - MaiDe Medical Industrial Equipment Co., Ltd. specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main products include safety infusion and blood purification equipment [1] - The company has been recognized with qualifications such as the establishment of a postdoctoral workstation in Zhejiang Province and participation in various provincial projects [1] Group 2: Financial Performance - As of the first quarter of 2025, the company reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87% [1] - The net profit for the same period was -10,797,370.24 yuan, reflecting a year-on-year decline of 202.70% [1] - The sales gross margin stood at 32.89% [1] Group 3: Institutional Holdings - As of the first quarter of 2025, five institutions held shares in MaiDe Medical, including three funds, one other institution, and one social security fund, with a total holding of 15.2835 million shares valued at 17.9 million yuan [1]

Group 1 - The chairman and general manager of Maide Medical, Wang Yuling, increased her shareholding by 296,400 shares at an average price of 12.67 yuan, totaling 3.756 million yuan, bringing her total holdings to 494,300 shares [1][2] - Maide Medical's main business includes the manufacturing of molds, industrial automation control systems, laboratory analysis instruments, plastic products, industrial robots, and specialized machinery with independent functions, as well as software development and information system integration services [1] - As of December 31, 2024, the revenue breakdown for Maide Medical shows that safety infusion line machines generated 116 million yuan (42.18%), blood purification line machines 104 million yuan (37.90%), safety infusion single machines 38.6 million yuan (14.04%), and other revenues 16.1 million yuan (5.87%) [1] Group 2 - The latest market capitalization of Maide Medical is 2.254 billion yuan [2]

Core Viewpoint - The announcement details the completion of a share buyback plan by Wang Yuling, the spouse of the company's controlling shareholder, Lin Junhua, indicating confidence in the company's future performance and stability [1][2]. Summary by Sections 1. Buyback Plan Disclosure - On April 11, 2025, the company disclosed a buyback plan where Wang Yuling intended to purchase shares worth between RMB 5 million and RMB 10 million over a six-month period starting from the announcement date [1]. 2. Implementation Results - From May 15 to May 26, 2025, Wang Yuling purchased a total of 492,300 A-shares, representing approximately 0.2962% of the company's total share capital, with a total transaction amount of RMB 6,027,173.02 (excluding transaction fees) [2][4]. - After the buyback, Lin Junhua and his concerted actions held a total of 84,593,940 shares, accounting for 50.8929% of the total share capital [2][4]. 3. Compliance and Legal Framework - The implementation of the buyback plan complies with relevant laws and regulations, including the Company Law of the People's Republic of China and the Securities Law [4][5]. - The buyback will not affect the distribution of shares required for listing, nor will it change the controlling shareholder or the governance structure of the company [5].

关于实际控制人之一致行动人增持股份结果的公告 迈得医疗工业设备股份有限公司 证券代码：688310 证券简称：迈得医疗 公告编号：2025-027 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：迈得医疗工业设备股份有限公司（以下简称"公司"） 于 2025 年 4 月 11 日在上海证券交易所网站（www.sse.com.cn）披露了《迈得医 疗工业设备股份有限公司关于实际控制人之一致行动人增持公司股份计划的公 告》（公告编号：2025-010）。公司控股股东、实际控制人、董事长、总经理林军 华先生的配偶王瑜玲女士拟自 2025 年 4 月 11 日起 6 个月内，以自有资金，通过 上海证券交易所交易系统允许的方式（包括但不限于集中竞价、大宗交易等）增 持公司股份，增持金额不低于人民币 500 万元（含）且不超过人民币 1,000 万元 （含）。本次增持计划不设置增持股份价格区间，将根据公司股票的价格波动情 况及资本市场整体趋势择机增持公司股份。 增持计划的实施结果：公司控股股东 ...

上海锦天城(杭州)律师事务所 法律意见书 上海锦天城(杭州)律师事务所 关于迈得医疗工业设备股份有限公司 实际控制人之一致行动人增持公司股份的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址:浙江省杭州市上城区富春路 308 号华成国际发展大厦 11/12 层 传真: 021-20511999 电话:0571-89838088 邮编：310020 上海锦天城(杭州)律师事务所 法律意见书 上海锦天城(杭州)律师事务所 关于迈得医疗工业设备股份有限公司 实际控制人之一致行动人增持公司股份的法律意见书 上锦杭【2025】法意字第 40527 号 致:迈得医疗工业设备股份有限公司 上海锦天城(杭州)律师事务所(以下简称"本所")接受迈得医疗工业设 备股份有限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》 (以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司收购管理办法》(以下简称"《收购管理办法》")等相 关法律、法规和规范性文件以及《迈得医疗工业设备股份有限公司章程》(以下 简称"《公司章程》")等内部规章制度的有关规定 ...

Core Viewpoint - The company has completed the election of its fifth board of directors and supervisory board, along with the appointment of senior management personnel, including the head of the audit department and the securities affairs representative [2][4][5]. Board of Directors Election - The company held its annual general meeting on May 20, 2025, where the fifth board of directors and supervisory board were elected, consisting of both non-employee and independent directors [2][3]. - Lin Junhua, Liu Xuetao, and Lin Junhui were elected as non-independent directors, while Wang Yaka, He Tao, and Zhang Yinghui were elected as independent directors, with Zhang Yinghui being a professional accountant [2][3]. Board Chairman and Committees - Lin Junhua was elected as the chairman of the fifth board of directors, with the term lasting until the end of the board's tenure [3]. - The board's specialized committees were formed, with independent directors holding a majority in the remuneration and assessment committee, audit committee, and nomination committee [3]. Supervisory Board Election - The supervisory board consists of non-employee representative supervisors and one employee representative supervisor, with a term of three years starting from the approval date of the annual general meeting [3][4]. Senior Management Appointments - The company appointed Lin Junhua as the general manager, Lin Dong as the deputy general manager and board secretary, and Lin Junhui as the financial officer, with terms aligned with the board's tenure [5][6]. - All appointed senior management personnel meet the qualifications required for their positions and have not faced penalties from regulatory authorities [6]. Audit Department Head Appointment - The company appointed Rao Shan as the head of the audit department, with a term that coincides with the board's tenure [4][6]. Securities Affairs Representative Appointment - Wu Shanshan was appointed as the securities affairs representative, assisting the board secretary, with qualifications meeting regulatory requirements [6][7].

金十数据5月21日讯，迈得医疗晚间公告，董事会会议同意选举林军华为公司第五届董事会董事长，同 意聘任林军华担任公司总经理，聘任林栋担任公司副总经理、董事会秘书，聘任林君辉担任公司财务负 责人。 迈得医疗：选举林军华为公司第五届董事会董事长 ...